Browsing by Author "Karavasilis, V."
Now showing items 1-20 of 25
-
Article
Angiogenesis in cancer of unknown primary: Clinicopathological study of CD34, VEGF and TSP-1
Karavasilis, V.; Malamou-Mitsi, Vassiliki D.; Briassoulis, E. Ch; Tsanou, E.; Kitsou, E.; Kalofonos, H. P.; Fountzilas, George; Fotsis, T.; Pavlidis, Nicholas (2005)Background: Cancer of unknown primary remains a mallignancy of elusive biology and grim prognosis that lacks effective therapeutic options. We investigated angiogenesis in cancer of unknown primary to expand our knowledge ...
-
Article
Association of ERCC1 SNPs with outcome in platinum-treated patients with advanced urothelial cancer: A Hellenic Cooperative Oncology Group study
Nikitas, N.; Karadimou, A.; Tsitoura, E.; Soupos, N.; Tsiatas, M.; Karavasilis, V.; Pectasides, Dimitrios; Pavlidis, Nicholas; Chrisofos, M.; Adamakis, I.; Murray, S.; Fountzilas, George; Dimopoulos, M. A.; Bamias, A. T. (2012)Aim: The association between two polymorphisms of ERCC1 and treatment outcomes after platinum-based chemotherapy in patients with advanced urothelial cancer (UC) was examined. Materials & methods: Genotyping of 19007C>T ...
-
Article
Biweekly administration of low-dose docetaxel in hormone-resistant prostate cancer: Pilot study of an effective subtoxic therapy
Karavasilis, V.; Briassoulis, E. Ch; Siarabi, O.; Pavlidis, Nicholas (2003)Taxane-based chemotherapy has shown activity but also toxicity when administered at standard doses in patients with hormone-resistant prostate cancer (HRPC). In this pilot study, we investigated biweekly low-dose docetaxel ...
-
Article
Chemotherapy for patients with two favourable subsets of unknown primary carcinoma: Active, but how effective?
Pentheroudakis, George; Briassoulis, E. Ch; Karavasilis, V.; Fountzilas, George; Xeros, N.; Samelis, G.; Samantas, E.; Pavlidis, Nicholas (2005)Carcinoma of unknown primary (CUP) is characterized by dismal patient survival. The outcome of patients with two favourable risk CUP subsets was studied. Eighty patients diagnosed with either midline lymph node metastases ...
-
Article
Clinicopathologic study of vascular endothelial growth factor, thrombospondin-1, and microvessel density assessed by CD34 in patients with stage III ovarian carcinoma
Karavasilis, V.; Malamou-Mitsi, Vassiliki D.; Briassoulis, E. Ch; Tsanou, E.; Kitsou, E.; Pavlidis, Nicholas (2006)The aim of the study was to investigate angiogenesis in patients with advanced-stage ovarian carcinoma. We used paraffin-embedded tumor tissues from 33 patients diagnosed with FIGO III ovarian cancer who had optimal surgery ...
-
Article
Clinicopathological study of metallothionein immunohistochemical expression, in benign, borderline and malignant ovarian epithelial tumors
Zagorianakou, N.; Stefanou, D. G.; Makrydimas, G.; Zagorianakou, P.; Briassoulis, E. Ch; Karavasilis, V.; Pavlidis, Nicholas; Agnantis, Niki J. (2006)Metallothioneins (MTs) are a family of cystein-rich metal-binding proteins, which are expressed in normal cells during fetal and postnatal life but also in a variety of human neoplasms. MT expression in human tumors has ...
-
Article
Clinicopathological study of the expression of hsp27, pS2, cathepsin D and metallothionein in primary invasive breast cancer
Ioachim, E.; Tsanou, E.; Briassoulis, E. Ch; Batsis, Ch; Karavasilis, V.; Charchanti, A.; Pavlidis, Nicholas; Agnantis, Niki J. (2003)Expression of the hormone-related proteins hsp27, pS2, and also of cathepsin D (CD) and metallothionein (MT) was studied by immunohistochemistry and analyzed against clinical data in breast cancer. Archived material of ...
-
Article
Clinicopathological study of the expression of syndecan-1 in invasive breast carcinomas. Correlation with extracellular matrix components
Tsanou, E.; Ioachim, E.; Briassoulis, E. Ch; Charchanti, A.; Damala, K.; Karavasilis, V.; Pavlidis, Nicholas; Agnantis, Niki J. (2004)Syndecan-1, a cell surface proteoglycan found predominantly on epithelia of mature tissues, binds both extracellular matrix (ECM) components and basic fibroblast growth factor (bFGF) and is implicated in the restriction ...
-
Article
Feasibility study and pharmacokinetics of low-dose paclitaxel in cancer patients with severe hepatic dysfunction
Briassoulis, E. Ch; Karavasilis, V.; Tzamakou, E.; Piperidou, C.; Soulti, K.; Pavlidis, Nicholas (2006)The aim of this study is to investigate the feasibility and determine the pharmacokinetics of low-dose paclitaxel in cancer patients with severe hepatic dysfunction. This was a prospective study. Patients with liver ...
-
Article
Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: Their prognostic value and role in tumour invasion and progression
Ioachim, E.; Charchanti, A.; Briassoulis, E. Ch; Karavasilis, V.; Tsanou, E.; Arvanitis, D. L.; Agnantis, Niki J.; Pavlidis, Nicholas (2002)The immunohistochemical expression of the extracellular matrix (ECM) components tenascin (TN), fibronectin (FN), collagen type IV (Coll) and laminin (LN), and their possible relationships were studied in a series of 134 ...
-
Article
Immunohistochemical expression of superoxide dismutase (MnSOD) anti-oxidant enzyme in invasive breast carcinoma
Tsanou, E.; Ioachim, E.; Briassoulis, E. Ch; Damala, K.; Charchanti, A.; Karavasilis, V.; Pavlidis, Nicholas; Agnantis, Niki J. (2004)The most important cellular protective mechanisms against oxidative stress are antioxidant enzymes. Their action is based on decomposal of reactive oxygen species (ROS) and their transformation to H2O2. Within the mitochondria ...
-
Article
Intensified bimonthly cisplatin with bolus 5-fluorouracil, continuous 5-fluorouracil and high-dose leucovorin (LV5FU2) in patients with advanced gastrointestinal carcinomas: A phase I dose-finding and pharmacokinetic study
Bamias, A. T.; Syrigos, K.; Fountzilas, George; Tzamakou, E.; Soulti, K.; Karavasilis, V.; Alamanos, Y. P.; Christodoulou, C.; Pavlidis, Nicholas (2004)5-Fluorouracil (5FU) and cisplatin are commonly used in the treatment of gastric cancer. Continuous 5FU appears to be more effective and less toxic than bolus administration, while increasing the dose intensity of cisplatin ...
-
Article
Interaction pharmacokinetis of pegylated liposomal doxorubicin (Caelyx) on coadministration with paclitaxel or docetaxel
Briassoulis, E. Ch; Karavasilis, V.; Tzamakou, E.; Rammou, D.; Soulti, K.; Piperidou, C.; Pavlidis, Nicholas (2004)Purpose: To investigate the pharmacokinetics of polyethylene glycol-coated liposomal doxorubicin (PLD, Caelyx) when given as a single agent and in combination with the taxanes paclitaxel or docetaxel in humans. Methods: ...
-
Article
Matrix metalloproteinases in carcinoma of unknown primary
Karavasilis, V.; Malamou-Mitsi, Vassiliki D.; Briassoulis, E. Ch; Tsanou, E.; Kitsou, E.; Kalofonos, H. P.; Fountzilas, George; Fotsis, T.; Pavlidis, Nicholas (2005)BACKGROUND. The purpose was to study proteolysis-related molecules, matrix metalloproteinase-2 (MMP-2) and MMP-9 and tissue inhibitor of metalloproteinases-1 (TIMP-1), in carcinoma of unknown primary (CUP). METHODS. ...
-
Article
Megestrol activity in recurrent adult type granulosa cell tumour of the ovary [2]
Briassoulis, E. Ch; Karavasilis, V.; Pavlidis, Nicholas (1997)
-
Article
Metastatic breast carcinoma confined to bone: Portrait of a clinical entity
Briassoulis, E. Ch; Karavasilis, V.; Kostadima, Lida; Ignatiadis, M.; Fountzilas, George; Pavlidis, Nicholas (2004)BACKGROUND. The current study was performed to study metastatic breast carcinoma that remains confined to bone. METHODS. The medical notes of 2514 breast carcinoma patients who were treated in 2 academic units over a 20-year ...
-
Article
Oxaliplatin (eloxatin™) plus irinotecan combination chemotherapy found effective in refractory metastatic insular thyroid carcinoma
Briassoulis, E. Ch; Rontogianni, D.; Karavasilis, V.; Pavlidis, Nicholas (2005)Therapeutic options for metastatic insular thyroid carcinoma (ITC) are very limited. We present the case of a 39-year-old woman with refractory metastatic ITC who responded to oxaliplatin plus irinotecan chemotherapy. She ...
-
Article
Pharmacodynamics of non-break weekly paclitaxel (Taxol) and pharmacokinetics of Cremophor-EL vehicle: Results of a dose-escalation study
Briassoulis, E. Ch; Karavasilis, V.; Tzamakou, E.; Haidou, C.; Piperidou, C.; Pavlidis, Nicholas (2002)We characterized the toxicity and determined the maximum tolerated dose of non-break weekly paclitaxel (Taxol) in chemotherapy-naive cancer patients, and studied pharmacokinetics of the formulation vehicle Cremophor-EL ...
-
Article
Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study
Pappas, P.; Karavasilis, V.; Briassoulis, E. Ch; Pavlidis, Nicholas; Marselos, M. (2005)Aim: To evaluate the pharmacokinetics of imatinib mesylate (Glivec) and its main metabolite (CGP74588) in a patient with end stage renal disease on hemodialysis and compare it with published data from subjects with normal ...
-
Article
Phase I trial of intravenous cisplatin-topotecan chemotherapy for three consecutive days in patients with advanced solid tumors: Parallel topotecan escalation in two fixed platinum dosing schemes
Pentheroudakis, George; Briassoulis, E. Ch; Karavasilis, V.; Mauri, D.; Tzamakou, E.; Rammou, D.; Pavlidis, Nicholas (2005)Purpose: We performed a phase I study of two fixed dosing schemes of cisplatin, a DNA cross-linker, with intravenous escalating topotecan, a DNA-topoisomerase I inhibitor. Experimental Design: 40 patients with advanced ...